In this episode, recorded live at the 2025 ASCO annual meeting, host Shikha Jain, MD, speaks with Sonali Smith, MD, about the power of mentorship and advocacy, preserving the academic mission of research within health care systems and more.

• Welcome to another exciting episode of Oncology Overdrive 1:34
• About Smith 1:56
• The interview 3:14
• What was your journey to get to where you are now in your career? 3:38
• How do you incorporate your advocacy work into patient care, and how do you advise other physicians on their advocacy journeys? 12:09
• Jain and Smith on how the politicization of health care has resulted in the rise of and demand for public physician advocacy. 13:32
• Jain and Smith on the impacts of today’s climate on clinical research work. 18:24
• Can you speak about your ELAM capstone project discussing how to preserve academics? 25:11
• Are there any lymphoma studies presented at ASCO this year that have excited you or interested/educated you? 31:54
• Jain and Smith on how ASCO underlines the importance of international collaboration in oncology research. 36:46
• If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 39:47
• How to contact Smith 40:27
• Thanks for listening 41:03

Sonali M. Smith, MD, is the Elwood V. Jensen professor of medicine, section chief of hematology/oncology, co-leader of the cancer service line, and co-director of the lymphoma program at the University of Chicago in the department of medicine. She is a clinical investigator in lymphoma and a clinical expert in Hodgkin and non-Hodgkin lymphomas.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Smith can be reached on LinkedIn or via email smsmith@bsd.uchicago.edu.

Disclosures: Jain and Smith report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Sadie Dobrozsi, MD, about the power of information in personalized oncology care, understanding the impacts of genetic testing and more.

• Welcome to another exciting episode of Oncology Overdrive 1:34
• About Dobrozsi 1:39
• The interview 2:03
• What was your path to this field of pediatric oncology, and how did you decide to focus on genetic testing? 2:33
• Can you talk about what it means to use genomics to optimize therapy and tailor precision medicine, and how you implement that in your work? 7:58
• Why is it so important to continue focusing on funding precision medicine as an advancement in cancer care? 10:34
• Can you talk about your work with BRCA research and how treatment and surgeries have evolved with our understanding of it? 14:30
• Jain and Dobrozsi on the importance of shared decision-making in oncology, and how genomics plays a role in that ongoing conversation. 20:18
• How do we navigate difficult conversations with increasingly younger patient populations, and why are we having these conversations more now than ever before? 23:55
• When it comes to genetic testing, how much knowledge is “good knowledge”? 27:05
• If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 34:31
• How to contact Dobrozsi 35:12
• Thanks for listening 35:39

Sadie Dobrozsi, MD, is a board-certified pediatric oncologist, a nationally recognized leader in complex care delivery, and the medical director of genetic testing and oncology imaging at Evolent, a leading specialty and primary care management company.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dobrozsi can be reached on LinkedIn or via email sdobrozsi@evolent.com.

Disclosures: Jain and Dobrozsi report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Abiola Ibraheem, MD, about the role culture plays in improving global oncology, launching the Best of ASCO in Africa and more.

• Welcome to another exciting episode of Oncology Overdrive 1:34
• About Ibraheem 1:42
• The interview 3:02
• How did you get where you are today? 3:28
• Can you tell me more about Aortic Africa and your role within the organization? 5:41
• What are some challenges you have encountered in doing this work, both locally and internationally? 7:33
• How have you navigated the nuances of global oncology in other countries? 9:51
• Did you get any pushback when you decided to create these global relationships and inroads? How did you navigate receiving different perspectives on your work? 12:10
• What are you hoping to achieve with these efforts in global oncology? 16:28
• Where did the idea for a Best of ASCO Africa come from, and what do you hope to achieve with the event? 17:41
• Jain and Ibraheem on the importance of providing other countries with tools to implement and drive global change. 22:54
• If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 27:29
• How to contact Ibraheem 28:09
• Thanks for listening 29:07

Abiola Ibraheem, MD, is a board-certified medical oncologist and assistant professor at the University of Illinois Chicago. Her journey in medicine began in Nigeria, where she earned her MBBS degree from Olabisi Onabanjo University. She then completed her internal medicine residency at Morehouse School of Medicine, focusing on racial health care disparities.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ibraheem can be reached via email at abiolai@uic.edu.

Learn more about Best of ASCO Africa, as well as how to sign up for in-person or virtual attendance, happening June 27 & 28 in Addis Abba, Ethiopia.

Disclosures: Jain and Ibraheem report no relevant financial disclosures.